Laura Sepp-Lorenzino

List of Publications by Year in Descending Order

62 papers	3,469 citations	32 h-index	58 g-index
68 ext. papers	4,010 ext. citations	6.9 avg, IF	4.65 L-index

#	Paper	IF	Citations
62	CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. *New England Journal of Medicine*, **2021**, 385, 493-502	59.2	180
61	Centyrin ligands for extrahepatic delivery of siRNA. *Molecular Therapy*, **2021**, 29, 2053-2066	11.7	6
60	Safety evaluation of 2′deoxy-2′fluoro nucleotides in GalNAc-siRNA conjugates. *Nucleic Acids Research*, **2019**, 47, 3306-3320	20.1	35
59	Systematic chemical modifications of single stranded siRNAs significantly improved CTNNB1 mRNA silencing. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 4513-4517	2.9	6
58	5′(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates. *ChemBioChem*, **2016**, 17, 985-9	3.8	73
57	Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor. *Cancer Chemotherapy and Pharmacology*, **2015**, 75, 333-42	3.5	
56	Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability. *Thrombosis and Haemostasis*, **2015**, 113, 1300-11	7	5
55	Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates. *Journal of Controlled Release*, **2014**, 183, 124-37	11.7	24
54	An in vivo evaluation of amphiphilic, biodegradable peptide copolymers as siRNA delivery agents. *International Journal of Pharmaceutics*, **2014**, 466, 58-67	6.5	9
53	Comparison of flow and batch polymerization processes for production of vinyl ether terpolymers for use in the delivery of siRNA. *Journal of Polymer Science Part A*, **2014**, 52, 1119-1129	2.5	1
52	Improving the in vivo therapeutic index of siRNA polymer conjugates through increasing pH responsiveness. *Bioconjugate Chemistry*, **2014**, 25, 296-307	6.3	15
51	A single dose of EGLN1 siRNA yields increased erythropoiesis in nonhuman primates. *Nucleic Acid Therapeutics*, **2014**, 24, 405-12	4.8	2
50	Novel endosomolytic poly(amido amine) polymer conjugates for systemic delivery of siRNA to hepatocytes in rodents and nonhuman primates. *Bioconjugate Chemistry*, **2014**, 25, 896-906	6.3	18
49	Expression of asialoglycoprotein receptor 1 in human hepatocellular carcinoma. *Journal of Histochemistry and Cytochemistry*, **2013**, 61, 901-9	3.4	61
48	Endosomolytic bioreducible poly(amido amine disulfide) polymer conjugates for the in vivo systemic delivery of siRNA therapeutics. *Bioconjugate Chemistry*, **2013**, 24, 640-7	6.3	31
47	Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2609-12	2.9	18
46	Pyridyl aminothiazoles as potent Chk1 inhibitors: optimization of cellular activity. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2613-9	2.9	8

45	Regulation of microRNA-145 by growth arrest and differentiation. *Experimental Cell Research*, **2011**, 317, 488-95	4.2	16
44	Effective siRNA delivery and target mRNA degradation using an amphipathic peptide to facilitate pH-dependent endosomal escape. *Biochemical Journal*, **2011**, 435, 475-87	3.8	52
43	Expression of micro-RNA-145 is regulated by a highly conserved genomic sequence 3Tto the pre-miR. *Journal of Cellular Physiology*, **2011**, 226, 602-7	7	9
42	Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. *International Journal of Pharmaceutics*, **2011**, 403, 237-44	6.5	49
41	Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses. *Molecular Therapy*, **2011**, 19, 567-75	11.7	42
40	Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. *Journal of Histochemistry and Cytochemistry*, **2011**, 59, 727-40	3.4	73
39	Quantitative evaluation of siRNA delivery in vivo. *Rna*, **2010**, 16, 2553-63	5.8	54
38	Noninvasive imaging of lipid nanoparticle-mediated systemic delivery of small-interfering RNA to the liver. *Molecular Therapy*, **2010**, 18, 1657-66	11.7	45
37	Immunohistochemical Detection of Antitumor, Antimetastasis, and Antiangiogenesis Effects of a Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor in an Orthotopic Breast Cancer Metastasis Model. *Journal of Histotechnology*, **2010**, 33, 15-24	1.3	1
36	An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. *Cancer Biology and Therapy*, **2010**, 9, 493-503	4.6	56
35	Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. *Molecular Therapy*, **2010**, 18, 171-80	11.7	134
34	Growth inhibition by microRNAs that target the insulin receptor substrate-1. *Cell Cycle*, **2009**, 8, 2255-9	4.7	18
33	Development of thioquinazolinones, allosteric Chk1 kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1240-4	2.9	65
32	Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 5989-94	2.9	38
31	Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 6280-5	2.9	21
30	An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. *Molecular and Cellular Biology*, **2007**, 27, 689-98	4.8	52
29	Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. *Journal of Biological Chemistry*, **2007**, 282, 32582-90	5.4	278
28	3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 6049-53	2.9	40

27	Development and implementation of multiplexed cell-based imaging assays. *Methods in Enzymology*, **2006**, 414, 284-300	1.7	7
26	Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 1146-50	2.9	29
25	Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2006**, 16, 5907-12	2.9	31
24	Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. *Cancer Cell*, **2005**, 8, 49-59	24.3	241
23	Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. *Molecular Cancer Therapeutics*, **2005**, 4, 413-25	6.1	19
22	A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. *Cancer Research*, **2004**, 64, 751-6	10.1	24
21	Analysis of the activating mutations within the activation loop of leukemia targets Flt-3 and c-Kit based on protein homology modeling. *Journal of Molecular Graphics and Modelling*, **2004**, 23, 153-65	2.8	8
20	Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR. *Bioorganic and Medicinal Chemistry Letters*, **2004**, 14, 909-12	2.9	38
19	Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. *Journal of Medicinal Chemistry*, **2004**, 47, 6363-72	8.3	51
18	Antiangiogenic agents targeting vascular endothelial growth factor and its receptors in clinical development. *Expert Opinion on Investigational Drugs*, **2002**, 11, 1447-65	5.9	30
17	LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 909-13	2.9	47
16	A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. *Chemistry and Biology*, **2001**, 8, 289-99		245
15	Synthesis and evaluation of geldanamycin-testosterone hybrids. *Bioorganic and Medicinal Chemistry Letters*, **2000**, 10, 1303-6	2.9	65
14	A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. *Cancer Chemotherapy and Pharmacology*, **2000**, 46, 79-83	3.5	13
13	Prostate cancer: therapeutic patent review. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 1833-1842	6.8	
12	Synthesis and evaluation of geldanamycin-estradiol hybrids. *Bioorganic and Medicinal Chemistry Letters*, **1999**, 9, 1233-8	2.9	89
11	Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues. *Journal of the American Chemical Society*, **1999**, 121, 2147-2155	16.4	388
10	Structure and function of the insulin-like growth factor I receptor. *Breast Cancer Research and Treatment*, **1998**, 47, 235-53	4.4	102

9	A Concise Total Synthesis of Dysidiolide through Application of a Dioxolenium-Mediated Diels–Alder Reaction. *Journal of the American Chemical Society*, **1998**, 120, 1615-1616	16.4	74
8	A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. *Journal of Biological Chemistry*, **1998**, 273, 20243-51	5.4	87
7	Cholesterol metabolism and tumor cell proliferation. *Sub-Cellular Biochemistry*, **1997**, 28, 363-435	5.5	23
6	Total Synthesis of Tryprostatin B: Generation of a Nucleophilic Prenylating Species from a Prenylstannane. *Journal of the American Chemical Society*, **1996**, 118, 12463-12464	16.4	71
5	Farnesyltransferase inhibitors and anti-Ras therapy. *Breast Cancer Research and Treatment*, **1996**, 38, 75-83	4.4	37
4	Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. *Journal of Biological Chemistry*, **1995**, 270, 16580-7	5.4	149
3	Isoprenylated proteins in myelin. *Journal of Neurochemistry*, **1994**, 62, 1539-45	6	9
2	Cell-cycle-dependent, differential prenylation of proteins. *FEBS Journal*, **1991**, 200, 579-90		18
1	Cellular distribution of cholesterogenesis-linked, phosphoisoprenylated proteins in proliferating cells. *FEBS Letters*, **1989**, 245, 110-6	3.8	34